The headlines of a newspaper on this page were generated automatically by a computer program.
このページのコンテンツは コンピュータプログラム で自動的に作成されています。
JAPANESE MAIN RSS feed RSS feed
updatenews @ hr.sub.jp
本システムについて





WORLD

BUSINESS

SPORTS

TECHNOLOGY

社会

政治

国際

経済

テクノロジー

スポーツ

エンターテイメント

科学
twitter hashtag summary
twitter trend
speech separation
large number Retweet
talking summarization
alarming description

real time translation turndown translation
      FDAのQnexaの合図は賞賛、Cripticismをスパークさせる


      the decision by a federal advisory panel on wednesday to recommend qnexa for approval by the u.s t food and drug administration is drawing praise and criticism from obesity and diet experts , reflecting a still-hot debate on the need for additional tools to treat obesity t t .
      米国tの食品医薬品局によって承認のためのqnexaを推薦する水曜日の中央政府諮問機関による決定は御馳走肥満t t.に付加的な用具のための必要性のまだ熱い討論を反映している肥満および食事療法の専門家からのデッサンの賞賛そして批評である。
      an advisory panel to the u.s food and drug administration on wednesday urged approval of a new obesity drug , qnexa , after warning against its approval in 2010 due to safety coincerns.the panel voted 20-2 that the fda should allow qnexa on the market , saying the latest overall benefit-risk assessment supported its approval.the drug , made by california-based biotech firm vivus , is the first obesity drug submitted to the fda in more than a decade .
      への諮問機関は安全concerns.theパネルによる2010の承認に対して警告の後で私達水曜日の食品医薬品局FDAが市場のqnexaを可能にするべきであること新しい肥満の薬剤の承認、qnexaを、投票した20-2年をせき立てた言最も最近の全面的な利点危険の査定はバイオテクノロジーのカリフォルニア基づかせていたしっかりしたvivusによってなされたapproval.theの薬剤をである十年より多くでFDAに堤出された最初の肥満の薬剤支えた。
      a u.s t food and drug administration advisory committee today recommended approval of the weight loss drug qnexa , a treatment many hope will help millions of americans who struggle with obesity t in voting  20 to 2 for approval , the committee said today that qnfxa’s weight loss.. t t .
      . .
      an fda panel backed vivus's qnexa , which could lead to approval of the first new prescription weight-loss drug in more than a decade .
      FDAは十年より多くの最初の新しい規定の重量損失の薬剤の承認をもたらすことができる支持されたvivusのqnexaにパネルをはめる。
      vivus shares doubled after a federal advisory panel overwhelmingly backed the weight-loss drug qnexa , clearing the way for u.s t approval of the first prescription diet drug in more than a decade .
      vivusの分け前は中央政府諮問機関が圧倒的に重量損失の薬剤のqnexaを支持した後倍増し、十年より多くの最初の新しい規定の食事療法の薬剤の米国tの承認の道を開く。
      everything you know about dieting is wrong , say us scientists who have devised a new formula for calculating calories and weight loss that they hope will revolutionize the way people tackle obesity.obesity rates have doubled worldwide in the past 30 years , coinciding with a growing food surplus , and the ensuing epidemic has sparked a multibillion dollar weight loss industry that has largely failed to curb the problem .
      あなたが食事療法について知っているすべては私達成長する食糧余剰と一致している科学者計算高いカロリーのための新しい方式を案出した望み、減量方法人々のタックルobesity.obesityが過去の30年に率世界的に倍増した方法人々を革命化するおよび続く伝染病は主として問題を抑制しなかった数十億の減量工業をスパークさせた悪事、言うである。
      an advisory panel to the us food and drug administration on wednesday urged approval of a new obesity drug , qnexa , after warning against its approval in 2010 due to safety coincerns.the panel voted 20-2 that the fda should allow qnexa on the market , saying the latest overall benefit-risk assessment supported its approval.the drug , made by california-based biotech firm vivus , is the first obesity drug submitted to the fda in more than a decade .
      あなたが食事療法について知っているすべては私達成長する食糧余剰と一致している科学者計算高いカロリーのための新しい方式を案出した望み、減量方法人々のタックルobesity.obesityが過去の30年に率世界的に倍増した方法人々を革命化するおよび続く伝染病は主として問題を抑制しなかった数十億の減量工業をスパークさせた悪事、言うである。
      everything you know about dieting is wrong , say us scientists who have devised a new formula for calculating calories and weight loss that they hope will revolutionize the way people tackle obesity.obesity rates have doubled worldwide in the past 30 years , coinciding with a growing food surplus , and the ensuing epidemic has sparked a multibillion dollar weight loss industry that has largely failed to curb the problem .
      vivusの分け前は中央政府諮問機関が圧倒的に重量損失の薬剤のqnexaを支持した後倍増し、十年より多くの最初の新しい規定の食事療法の薬剤の米国tの承認の道を開く。
      a u.s t food and drug administration advisory committee today recommended approval of the weight loss drug qnexa , a treatment many hope will help millions of americans who struggle with obesity t in voting  20 to 2 for approval , the committee sailed today that qnfxa’s weight loss.. t t .
      . .
      the decision by a federal advisory panel on wednesday to recommend qnexa for approval by the u.s t food and drug administration is drawing praise and criticism from obesity and diet experts , reflecting a still-hot debate on the need for additional tools to treat obesity t t .
      vivus shares doubled after a federal advisory panel overwhelmingly backed the weight-loss drug qnexa , could learing the way for u.s t approval of the first prescription diet drug in more than a decade .
      everything you know about dieting is wrong , say us scientists who have devised a new formula for calculating calories and weight loss that they hope will change the way people tackle obesity .
      an fda panel backed vivus's qnexa , which could lead to approval of the first new prescription weight-loss drug admin more than a fedecade .
      Generated 2012-2-24_11:16





blogsphere accumulation         blog